International Business Leader with 35+ years in the pharmaceutical industry, covering multiple geographies including the US, Europe, and the Middle East. Assumed number of executive leadership roles including Global VP & Commercial Chair Infectious Diseases at Wyeth Global HQ in the US, and Regional Managing Director of Wyeth Pharmaceuticals for MENA. Joe held an active role in industry committees, including PhRMA MEAC Board as the Vice Chair and the Chair for the PhRMA MEAC Ethics Review Board. He is still active and engaged in numerous international compliance forums

Qais is founder and CEO of Kuwait Life Sciences Company a unique healthcare company which focuses on healthcare innovative concepts and demanded services that have a clear unmet need. KLSC is designed as an integrated healthcare company building unique projects and is considered one of the few venture capitalists in the Middle East that invests globally and operates regionally seeking to advance healthcare services and systems in the region. Qais moved to KLSC after being responsible for the Life Sciences Investment Projects at the parent company 'National Technology Enterprises (NTEC)' since 2006. NTEC was created to play a vital role in servicing major stakeholders in Kuwait with their technology needs. Prior to NTEC, Qais managed a portfolio of private equity funds & direct investments in addition to fund raising and servicing clients at the Industrial & Financial Investments Co. (IFIC) for 8 years. He was also a member of the Investment Committee and involved in structuring investment portfolios and funds including a series of U.S. based Venture Leasing Funds. Qais holds a bachelor degree in Electrical Engineering from Kuwait University and as well as serving on the Board of Orient, he also currently serves as the Chairman of the Board of Clinart MENA.

Caley is a founder and managing member of Kearny Venture Partners and KVP Capital. Caley is a current board member of Alivecor, Boreal, Orient Pharmaceuticals, ViewRay, WellPartner, and Waterstone Pharmaceuticals. At Kearny, his previous investments include Aspreva (acquired by Gelenica), CoTherix (acquired by Actelion), Kai (acquired by Amgen), Roxro (acquired by a unit of Daiichi Sankyo), and QuatRx (partnered with Shionogi). Caley received his M.D. from the University of California, San Francisco, with honors. During medical school, he ran a research program investigating the genetic causes of deafness and the application of gene therapy to treatment of hearing loss. The findings were published in leading journals including Nature Genetics. After medical school, Caley completed a general surgery internship at the University of California, San Francisco. He received an A.B. magna cum laude from Harvard College.

Andrew is a graduate of UC Berkeley; having started his career in Audit with Andersen, he has subsequently held a number of senior financial positions with Sanderling Ventures, Gryphon Investors, IIX and Clairvue Capital Partners before joining Kearny Venture Partners as CFO in 2008.

The Group CEO of the National Technology Enterprises Company; a fully owned subsidiary of the Kuwait Investment Authority with an authorized capital of KD. 100mn - $350mn - specializes in developing and financing technology projects locally and regionally with vast technology VC investments internationally. Throughout his 22 years of career experience, Anas Meerza has served well over 11 years as a Research Associate at the Kuwait Institute for Scientific Research (KISR) Energy Department, and in parallel has started several companies in Kuwait, the region and the US specializing in Industrial Applications, Information Technologies, Telecommunications, Software Development, Healthcare Management and Advisory Services. Anas Meerza holds a BSc. in Mechanical Engineering Technology from the University of Dayton, Ohio, USA, since 1994, Executive Education in Leadership, Innovation and Global Sales from MIT, Executive Education in Business Administration from UC San Diego and Executive Education in Global Business Performance from IMD Switzerland. Anas Meerza is also a lecturer in Entrepreneurship and Business Management & Start-ups in several universities, colleges and specialized centers, and he is also a consultant and a board member in several local, regional and international companies and institutes

Subhi has more than 35 years of extensive healthcare management experience. He was most recently General Manager of Baxter Healthcare Middle East & Africa, UAE from 2013-2016 and previously held the positions of Vice President of Middle East, Turkey & Africa for Medtronic in Lebanon; Group Vice President of Asia, Australasia, Middle East for ICN Pharmaceuticals in California; Managing Director of Suzhou Lederle and Chairman & Managing Director of Cyanamid Pakistan. Subhi has a proven track record in in the Asia/Pacific, Middle East & Africa Regions establishing new businesses and distributor networks, opening new markets and restructuring operations. He is highly skilled at managing pharmaceutical and medical devices operations at both country and regional level with significant achievements in recruiting and developing winning teams to deliver sustainable growth.

Taghreed is Founder and CEO of Professional Effective Solutions, offering consultation to pharma companies working in the MENA region in formulating effective business plans; new product launch strategies as well as turnaround management to assure turnaround success. She has 24+ years of in-depth experience in pharma including technical, regulatory, sales and marketing, business development coupled with exceptional motivational communication and people skills. Taghreed has extensive international experience with a great focus and understanding of MENA. She held the role of Executive Vice President for Strategic Business Development at Hikma Pharmaceutical until March 2011. She played an instrumental role in the growth and success of Hikma in the MENA region leading the business to increase net revenue of its branded division from $53M in 2003 up to $353M in 2009 and contributing around 63.5% of Hikma's total world-wide revenue. She was also an important member of the IPO team that helped take Hikma from a local Jordanian company to an internationally recognized public company listed on the London Stock Exchange in November 2005.